Establishment and practical effect evaluation of human blood albumin control scheme in cancer hospital
摘要
目的 构建肿瘤患者人血白蛋白的管控模式,促进人血白蛋白的临床合理用药.方法 制定人血白蛋白评价标准,形成药学干预与行政监督的管理模式.采用回顾性研究方法,调取出院日期为2024年1月1日—3月31日(干预前)及2024年5月1日—7月31日(干预后)所有使用人血白蛋白的住院患者的病历,分析干预前和干预后人血白蛋白的使用情况.结果 干预后人血白蛋白的使用率较前下降1.84%(P=0.000),总消耗量较前减少18 730 g(P=0.049),使用金额较前下降5.22%(P=0.030),不合理使用率较前下降4.53%.进行Bonferroni多重检验校正后,人血白蛋白干预前后总消耗量和使用金额均未达到统计学显著性水平(P>0.007).结论 本院人血白蛋白干预前后使用率的差异具有临床价值,证明构建的人血白蛋白管控模式有效、可行,可为临床合理用药提供参考,避免医疗资源浪费.
Objective To establish a management scheme for human albumin in cancer patients,promoting the reason-able clinical use of human albumin.Methods Formulate evaluation criteria for human albumin,establishing a management model that combines pharmaceutical intervention and administrative supervision.A retrospective study was conducted,ex-amining the medical records of all in-patients who used human albumin between January 1 and March 31,2024(pre-inter-vention),and between May 1 and July 31,2024(post-intervention),to analyze the usage of human albumin before and after the intervention.Results The use of human albumin after the intervention decreased by 1.84%(P=0.000),total consump-tion was reduced by 18 730 g(P=0.049),the amount spent decreased by 5.22%(P=0.030),and the rate of inappropriate use decreased by 4.53%.After Bonferroni multiple comparison correction,neither the total consumption of human albumin nor the spending reached a statistically significant difference(P>0.007).Conclusion The difference in the usage of human albumin pre-and post-intervention in our hospital has clinical value,proving the established human albumin manage-ment scheme is effective and feasible.It can provide guidance for the clinical rational use of drugs,thus avoiding wasting medical resources.